How Eli Lilly Transforms Medicine Through People Centered Technology Leadership

The Human-Centric Approach to Technological Transformation in Healthcare

The intersection of technology and healthcare delivery is experiencing a fundamental shift, with people - not just systems - at its core. This insight emerges clearly from a recent interview with Diogo Rau, Chief Information and Digital Officer at Eli Lilly and Company, who shares how the pharmaceutical giant is reshaping its approach to technology implementation and talent development.

Rau's Core Argument: People First

Rau's central argument is straightforward yet profound: successful technological transformation in healthcare depends primarily on people, not just technical capabilities. This perspective shapes everything from hiring practices to project execution at Eli Lilly.

Supporting Arguments

• Technical leadership must start at the top - exemplified by Lilly's CEO completing hands-on AI coding courses alongside technical staff.
• Fresh thinking requires regular role rotation, with Rau having moved all his direct reports to new positions within three years.
• Technical expertise must be prioritized in hiring, with 90% of recent technology hires being capable coders and developers.

Research Supporting a People-Centric Approach

Research from Deloitte's 2023 Life Sciences Technology Trends report supports Rau's approach, indicating that pharmaceutical companies prioritizing technical talent development are 2.5 times more likely to successfully implement digital transformation initiatives. Additionally, McKinsey's 2023 Global Survey on AI adoption shows that organizations emphasizing internal capability building outperform those relying primarily on external vendors.

Case Study: LillyDirect

The impact of this people-centered approach is evident in Lilly's development of LillyDirect, their direct-to-consumer platform. Rather than outsourcing, the company built the platform in-house in just 12 weeks - an unprecedented timeframe in an industry accustomed to 12-month development cycles. This success demonstrates how internal capability building can accelerate innovation.

Looking to the Future

Rau's vision extends beyond current projects to the future of the pharmaceutical industry itself. He predicts that technology adoption - particularly AI implementation - will determine which companies thrive over the next 15-20 years. However, he maintains that success will depend not on technology alone, but on organizations' ability to develop and retain technical talent.

Organizational Structure and Strategy

This talent-first approach also influences organizational structure. Rau has moved away from traditional IT department terminology, rebranding as 'tech at Lilly' to reflect a broader mission. He's also rejected the customer-supplier mindset between technology teams and business units, instead fostering true partnerships where success is mutually dependent.

AI Implementation at Lilly

The implementation of AI across Lilly exemplifies this balanced approach. While embracing tools like ChatGPT company-wide, Rau emphasizes the need for specialized AI solutions in different areas - from small molecule discovery to genetic medicine development. Each application requires not just sophisticated technology, but also skilled professionals who understand both the technical and business contexts.

Success Stories and Achievements

Recent success stories support this strategy. Lilly's AI-driven drug discovery programs have accelerated development timelines, while their consumer-facing technologies have improved patient access to medications. These achievements stem from combining technical capabilities with deep healthcare expertise.

Conclusion: Lessons for the Industry

Looking ahead, Rau's insights suggest a broader evolution in how pharmaceutical companies approach technology leadership. The traditional focus on managing IT systems is giving way to a more nuanced role that combines technical expertise with people development and strategic partnership.

Lessons for Other Organizations

• Technical leadership must extend beyond the IT department to the highest levels of the organization.
• Internal capability building should take precedence over outsourcing.
• Organizational structures should support collaboration rather than reinforce silos.

Implications for the Pharmaceutical Industry

The implications for the pharmaceutical industry are significant. As technology becomes increasingly central to every aspect of drug development and healthcare delivery, companies that successfully blend technical capabilities with human expertise will have a distinct advantage.

This synthesis of technology and human capability represents a new paradigm in healthcare innovation. While advanced technologies like AI will continue to drive progress, the key differentiator will be organizations' ability to develop and deploy human talent effectively.

Final Thought

The experience at Eli Lilly demonstrates that successful digital transformation in healthcare requires more than just implementing new technologies. It demands a fundamental shift in how organizations think about and develop their people. As the industry continues to evolve, this people-centered approach to technology leadership may well become the standard for success.